


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
COMPLETION OF ISSUANCE OF FIRST TRANCHE OF PANDA BONDS

The board of directors (the “Board”) of Sino Biopharmaceutical Limited (the “Company”, together with its subsidiaries, the “Group”) announces that the Company recently has completed the issuance of the first tranche of panda bonds. Based on the bookbuilding and placement results, the total issue size of the first tranche of panda bonds is RMB1.5 billion, with a coupon rate of 1.95% and a maturity of 180 days. To the best of the knowledge, information and belief of the directors of the Company, having made all reasonable enquiries, each of the underwriters for the issuance of the first tranche of panda bonds and the subscribers of the first tranche of panda bonds is a third party independent of the Company and its connected persons (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited).

The issuance of the first tranche of panda bonds is intended to proactively explore diversified financing channels and reduce the cost of capital of the Company. The Group has a consistently prudent financial planning and robust capital base. The issuance of panda bonds will further optimise the financing structure of the Group and enhance its financial performance. Meanwhile, it shows the capability of the Group in the aspect of financial creativity and market expansion, acting as a concrete action responding to the national policies of supporting the development of biopharmaceutical industry.

Relevant documents in relation to the issuance of the first tranche of panda bonds were published on the website of Shanghai Clearing House (<http://www.shclearing.com.cn>).

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 20 June 2024

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.